{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:08:17Z","timestamp":1775840897626,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaut.2024.103244","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T10:40:25Z","timestamp":1716633625000},"page":"103244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients"],"prefix":"10.1016","volume":"147","author":[{"given":"Rebecca","family":"Favaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-9854","authenticated-orcid":false,"given":"Paola","family":"Facheris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Formai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta Valeria","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Avagliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santo Raffaele","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaut.2024.103244_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2024.103244_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","article-title":"Psoriasis: a mixed autoimmune and autoinflammatory disease","volume":"49","author":"Liang","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2024.103244_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2004.02310.x","article-title":"Immunopathogenic mechanisms in psoriasis","volume":"135","author":"Gudjonsson","year":"2004","journal-title":"Clin. Exp. Immunol."},{"issue":"10148","key":"10.1016\/j.jaut.2024.103244_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaut.2024.103244_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"13","key":"10.1016\/j.jaut.2024.103244_bib6","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103244_bib7","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.jaut.2024.103244_bib8","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1084\/jem.20160258","article-title":"Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a","volume":"213","author":"Cheung","year":"2016","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.jaut.2024.103244_bib9","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jaut.2024.103244_bib10","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"10.1016\/j.jaut.2024.103244_bib11","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.283","article-title":"Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study","volume":"101","author":"Borroni","year":"2021","journal-title":"Acta Derm. Venereol."},{"issue":"10","key":"10.1016\/j.jaut.2024.103244_bib12","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s13555-022-00795-x","article-title":"Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"4","key":"10.1016\/j.jaut.2024.103244_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2340\/0001555577273276","article-title":"Evidence that HLA-Cw6 determines early onset of psoriasis, obtained using sequence-specific primers (PCR-SSP)","volume":"77","author":"Enerb\u00e4ck","year":"1997","journal-title":"Acta Derm. Venereol."},{"issue":"11","key":"10.1016\/j.jaut.2024.103244_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15793","article-title":"Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: a multicentric retrospective study","volume":"35","author":"Ricceri","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"3","key":"10.1016\/j.jaut.2024.103244_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-0625.2011.01423.x","article-title":"Cost-effective HLA-Cw06:02 typing in a Caucasian population","volume":"21","author":"Nikamo","year":"2012","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jaut.2024.103244_bib16","article-title":"A risankizumab super responder profile identified by long-term real-life observation-IL PSO (Italian LANDSCAPE PSORIASIS)","author":"Gargiulo","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.jaut.2024.103244_bib17","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"The Lancet Rheumatology"},{"issue":"4","key":"10.1016\/j.jaut.2024.103244_bib18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.jid.5700118","article-title":"Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--an analysis of 1019 HLA-C- and HLA-B-typed patients","volume":"126","author":"Gudjonsson","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.jaut.2024.103244_bib19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/503821","article-title":"Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene","volume":"78","author":"Nair","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"9","key":"10.1016\/j.jaut.2024.103244_bib20","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jid.2016.04.033","article-title":"Binding Affinity and Interaction of LL-37 with HLA-C*06:02 in psoriasis","volume":"136","author":"Mabuchi","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.jaut.2024.103244_bib21","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T20:30:35Z","timestamp":1720816235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":21,"alternative-id":["S0896841124000787"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103244","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103244"}}